NYSE
12.16USD
-0.03 (-0.21%)
We have scored 13 news catalysts on Dr. Reddy's Laboratories Limited (RDY) over the past 12 months. The biggest single-day move next to one of them came Jul 12, 2026, when RDY closed −5.0%: “Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk”. Coverage across the window leans positive (average ticker sentiment +0.22). Most of the impact sits in sector healthcare and pricing power structural.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
10.1B
P/E
—
EPS
—
Beta
0.25
52W range
11.36-15.67
Day range
12.16–12.26
Open
12.18
Prev close
12.19
Volume
296.8K
Avg volume
2.7M
Dividend
0.08
IPO
2001-04-11
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Dr. Reddy's Laboratories Limited — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for RDY: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.
